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Abstract
Background: Complete Congenital Heart Block (CCHB) is a rare disease of the newborn that carries significant morbidity and mortality. 
CCHB can be diagnosed early or late in life. In newborns, it is usually associated with maternal autoantibodies or a congenital cardiac 
structural abnormality. The most common presentation of CCHB is bradycardia that can be diagnosed by an electrocardiogram. Results: 
This is a case report of a male infant born to a mother with an autoimmune disease, Systemic Lupus Erythematosus (SLE), who was found 
to have third degree heart block at birth. Conclusion: Early diagnosis and prompt management of the case is important for a better prog-
nosis and prevention of associated complications. Neonates with CCHB should be managed at a tertiary care center and the only definite 
treatment is insertion of a pacemaker. Moreover, prenatal diagnosis and specific obstetric counseling of pregnant women with SLE along 
with careful monitoring with serial ultrasonography and echocardiography are of paramount importance in prevention of the disease in 
subsequent offspring.
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Introduction
Complete Congenital heart block (CCHB) is a rare clinical entity 
present in about 1 in 20,000 live births and has significant mor-
bidity and mortality.1 It generally occurs due to the presence 
of maternal auto-antibodies, anti-Ro/SSA and anti-La/SSB, that 
are transferred across the placenta to the fetus and affect the 
fetal heart. More rarely, it may be associated with a congenital 
structural abnormality of the heart.2-3 The association between 
CCHB and maternal autoantibodies has been documented in 
different case reports.4-8 
The risk of Neonatal Lupus Erythematosus (NLE) or Congenital 
Heart Block (CHB) is 1% in infants with positive maternal au-
toantibodies to SSA/Ro. The risk is much higher if the mother 
already has had a child with NLE or has hypothyroidism due 
to thyroid autoantibodies that test positive for anti-Ro/SSA an-
tibodies.2 The most common clinical manifestations of NLE are 
related to the cardiac, dermatologic and hepatobiliary systems. 
Some infants may also have hematologic, central nervous sys-
tem or splenic abnormalities.9-10 Infants with NLE have 15-30% 
risk of developing CHB.2,11 
In the early part of 19th century, congenital heart block was 
clinically recognized by slow pulse, syncopal attacks and ECG 
findings consistent with complete atrio-ventricular block lea-
ding to the death of the child early on in infancy.12-13 Con-
siderable information has also been accumulated since then 
concerning the clinical profile and circulatory hemodynamics in 
such cases.14-15 Mortality is highest in the neonatal period and 
association with major cardiac malformations is a bad prognos-
tic sign.16 We present a rare case of Complete Congenital Heart 
Block (CCHB) in a newborn associated with maternal Systemic 
Lupus Erythematosus (SLE). A written informed consent was 
obtained from the parents of the patient for the publication of 
the available data.
The Case
A 3-days-old full-term male infant, born out of a consangui-
neous marriage by normal vaginal delivery with a birth wei-
ght of 3,330 g, presented with bradycardia (heart rate of 40-65 
beats/min) and respiratory distress for which he was admitted 
to special care baby unit (SCBU). His mother, Gravida 6 and 
Para 6, had a past medical history significant for Systemic Lu-
pus Erythematosus (SLE) as positive anti-Ro/SS-A antibodies 
had been discovered 5 years ago. Her antibody titers have 
been persistently elevated since then.  Furthermore, she has 
had persistent hypothyroidism over the past four years which 
currently being treated with levothyroxine. Also, two of her 
previously offspring were found positive when tested for Anti-
nuclear Antibody (ANA) and anti-Ro/SSA antibodies. 
The infant was stabilized in the SCBU and kept on two liters of 
oxygen through nasal cannula for respiratory distress. He was 
tolerating feeds. His heart rate ranged between 40-65 beats/
min despite being given two doses of atropine (0.1 mg/dose). 
Laboratory examinations showed capillary blood sugar of 72 
mg/dl, normal complete blood count and normal electrolyte 
levels (Na- 137 meq/L, K-3.6 meq/L). At presentation, the arte-
rial blood gas analysis (pH-7.25, pCO2-58 mmHg, pO2-40 mmHg, 
HCO3- 24 mmHg and base excess of -4) showed respiratory aci-
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dosis. Chest X-ray AP view showed cardiac enlargement (Figure 
1). His electrocardiogram (ECG) showed features of complete 
heart block (Figure 2). Based on his condition, it was decided 
to do further evaluation and management (including the possi-
bility of pacemaker insertion) to support the patient in the best 
possible way. Echocardiography was performed and it revealed 
no structural abnormality. A permanent pacemaker (St. Jude 
VVI PM at rate 90 beats/min) implantation was done on the 8th 
day of the infant’s life. Upon further follow up, the patient was 
stable and his general health status was good. The pacemaker 
was functioning well at a rate of 90 beats/min. He was thriving 
well with normal development.
Discussion
SLE is an autoimmune disease characterized by production of 
large amounts of circulating autoantibodies that can affect any 
organ of the body and leads to variable clinical manifestations. 
The ANA is the most sensitive laboratory test for the diagnosis 
of SLE.17 The presence of anti-double stranded DNA antibodies 
Figure 2. ECG from Infant Demonstrating Complete Congenital Heart Block
Note: ECG of the infant demonstrates no relation between P wave and QRS complex. The P wave has the normal rate and is regular, as it is arising from the 
sino-atrial node. The QRS complex illustrates the ventricular escape rhythm and hence is very slow.
Figure 1. Anteroposterior (AP) Chest Radiograph of the Infant
Note: Chest radiograph showed cardiac enlargement.
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and anti- Smith antibodies are more specific for the diagnosis 
of SLE as they have high sensitivity. Other nonspecific subtypes 
of ANA can be associated with SLE, including antibodies to Ro 
(SSA) and La (SSB), but these are also seen in patients with 
Sjogren’s syndrome. Studies have shown that congenital heart 
block is associated with maternal connective tissue diseases 
such as SLE and in patients with structural heart disease such 
as L-transposition of the great arteries.18-19 CCHB can also be 
observed in patients with neonatal lupus syndrome diagnosed 
in utero.20
 
Among the conduction defects resulting from maternal SLE, 
congenital heart block in infants born to mothers with anti-Ro 
antibodies is the most commonly seen in clinical practice.21 The 
anti Ro antibodies have been detected in maternal sera in up 
to 98% of cases of CCHB.22 Antibodies to Ro/SSA are detected by 
enzyme-linked immunosorbent assay (ELISA) and Western blot 
immunodiffusion tests. The Ro/SSA autoantigen consists of two 
proteins, Ro52 and Ro660, with the former having close correla-
tion with the development of CCHB.23 These antibodies induce 
myocarditis which leads to CCHB by destroying the cardiac con-
duction system at the atrioventricular node and bundle of His 
region. Atrioventricular (AV) block occurs due to impairment in 
the conduction system causing delay or block in transmission 
of atrial impulse to ventricles. Third-degree heart block, whe-
ther its congenital or acquired, is diagnosed when there is no 
association between P wave and QRS complexes. In less than 
10% of cases, congenital AV block may be either 1st or 2nd de-
gree block at birth, of which 50% progress to 3rd-degree block 
in postnatal life.15 Congenital heart block can be detected in 
utero between 18 and 28 weeks of gestation by echocardiogra-
phy in the presence of fetal bradycardia.24-25 It may also be as-
sociated with other cardiac abnormalities such as endocardial 
fibroelastosis and dilated cardiomyopathy.26 As the fetal heart 
rate is an important indicator for the prognosis during the new-
born period, the persistent bradycardia may eventually lead 
to increased size of both right and left ventricles.16 In children 
under three years of age, a heart rate less than 100 beats/min 
is considered as bradycardia.1 Our patient had a heart rate of 
40-65 beats/min, whereas normal newborns have a heart rate 
of 120-160 beats/min. In spite of his low heart rate, his birth 
weight was within normal limits. The ECG showed the most 
severe type of heart block, third degree heart block, where 
there is no transmission of atrial impulse to the ventricle. CCHB 
is the most serious complication associated with maternal SLE 
and once established it is irreversible.3 
Occasionally, these cases are symptomatic in the neonatal pe-
riod, as evident in our case, and they are considered high-risk 
patients requiring urgent intervention. The mortality is highest 
during the neonatal period. Glucocorticoid therapy is suggested 
for management of CCHB in utero and in the perinatal period 
(if associated with anti-Ro and anti-La antibodies), but the the-
rapy itself carries high risk to both the mother and the fetus.27 
Two third of all congenital heart block patients require pace-
maker implantation and it is recommended in symptomatic br-
adycardia. Pacemaker therapy is recommended in infants with 
CCHB and heart rates less than 55 beats/min in the absence of 
structural heart disease or with rates less than 70 beats/min 
with concomitant congenital heart disease or signs of ventricu-
lar dysfunction. Beyond the first year of life, a heart rate less 
than 50 beats/min or abrupt pauses in ventricular rate merit 
consideration of pacing therapy. Evidence of cardiomyopathy 
with ventricular dysfunction, complex ventricular ectopy and 
wide complex escape rhythm are also indications for pacing.28 
The primary goal of the pacemaker is to prevent sudden car-
diac death and to provide symptomatic relief with improve-
ment in quality of life and functional capacity, as was done in 
our case.22,29
Conclusion
In conclusion, anticipation of CCHB in cases of maternal SLE is 
important. Early detection of CCHB by health care professio-
nals and timely management is the key to the success of the 
infant’s survival. A thorough physical examination and an ECG 
can be diagnostic in patients presenting with bradycardia. For 
prevention, it is necessary to implement: 1) Health education 
and creating awareness among high risk populations, 2) Em-
phasize good antenatal care and proper screening, especially 
in underprivileged populations, because frequent assessment 
of fetal heart rate by echocardiography during pregnancy is 
beneficial for a patient with positive anti-Ro and anti-La anti-
bodies, and 3) implementing proper obstetric counseling and 
support to the family. 
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